Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain;Análisis de coste-efectividad de dapagliflozina en comparación con los inhibidores de la DPP4 y otros antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2 en España

Atencion Primaria

Volumn 47, Issue 8, 2015, Pages 505-513

  Abad Paniagua, Eduardo José ^a   Casado Escribano, Pedro ^b   Fernández Rodriguez, José María ^c   Morales Escobar, Francisco J ^d   Betegón Nicolás, Lourdes ^e   Sánchez Covisa, Joaquín ^f   Brosa, Max ^g  

^a Centro de Salud Las Aguilas   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL SEVERO OCHOA   (Spain)

^d Centro de Salud de Arucas   (Spain)

^e BRISTOL MYERS SQUIBB   (United States)

^f ASTRAZENECA   (United Kingdom)

^g Oblikue Consulting   (Spain)

Author keywords

Costs; Dapagliflozin; Diabetes; DPP4 inhibitors; Sulphonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DAPAGLIFLOZIN; METFORMIN; SULFONYLUREA;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SPAIN;

EID: 84944146328     PISSN: 02126567     EISSN: 15781275     Source Type: Journal    
DOI: 10.1016/j.aprim.2014.11.002     Document Type: Article

References (37)

1. C. Crespo, M. Brosa, A. Soria-Juan, A. López-Alba, N. López-Martínez, and B. Soria Costes directos de la diabetes mellitus y de sus complicaciones en España. Estudio SECCAID Av Diabetol. 29 2013 182 189
2. A. Sicras-Mainar, R. Navarro-Artieda, and J. Ibáñez-Nolla Características clínicas y económicas asociadas a la diabetes tipo 2 Rev Clin Esp. 214 2014 121 130
3. E. Menéndez, F.J. Lafita, S. Artola, J. Millán, A. Alonso, M. Puig, and et al. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2 Aten Primaria. 43 2011 202 e1-9
4. ® (dapagliflozina). Agencia Europea del Medicamento [consultado 1 Dic 2013]. Disponible en: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002322/WC500136024.pdf
5. ®). Agencia Europea del Medicamento [consultado 1 Dic 2013]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/002322/WC500136026.pdf/
6. M.A. Nauck, S. del Prato, J.J. Meier, S. Durán-García, K. Rohwedder, M. Elze, and et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care. 34 2011 2015 2022
7. J. López-Bastida, J. Oliva, F. Antoñanzas, A. García-Altés, R. Gisbert, J. Mar, and et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias Gac Sanit. 24 2010 154 170
8. P. McEwan, M. Evans, and K. Bergenheim A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes Diabetes Obes Metab. 12 2010 623 630
9. RedGDPS. Práctica clínica en la DM2. Análisis crítico de las evidencias por la redGDPS. 2010 [consultado 1 Dic 2013]. Disponible en: http://www.redgdps.org/gestor/upload/file/guias/guia-gedaps-practica-cinica-2010.pdf
10. M.J. Divins Hipoglucemiantes no insulínicos. Un segmento atomizado Farmacia Profesional. 26 2012 25 31
11. S.M. Goring, N. Hawkins, G. Wygant, M. Roudaut, R. Townsend, I. Wood, and et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis Diabetes Obes Metab. 16 2014 433 442
12. Oxford Outcomes, Network Meta-Analysis of Anti-Diabetic Agents in Type 2 Diabetes Mellitus. Metformin add-on therapy (report and data on file). November 2011.
13. ®). Agencia Europea del Medicamento [consultado 1 Dic 2013]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/000285/WC500021386.pdf
14. P.M. Clarke, A.M. Gray, A. Briggs, A.J. Farmer, P. Fenn, R.J. Stevens, and et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) Diabetologia. 47 2004 1747 1759
15. M. Monami, N. Marchionni, and E. Mannucci Long-acting insulin analogues vs. NPH human insulin in type 2 diabetes. A meta-analysis Diabetes Res Clin Pract. 81 2008 184 189
16. N. Waugh, E. Cummins, P. Royle, C. Clar, M. Marien, B. Richter, and et al. Newer agents for blood glucose control in type 2 diabetes: Systematic review and economic evaluation Health Technol Assess. 14 2010 1 248
17. C. Fajardo, C. Hernández, and M. Rivas Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: The PREDICTIVE BMI clinical trial Diabet Med. 25 2008 916 923
18. P. Clarke, A. Gray, and R. Holman Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) Med Decis Making. 22 2002 340 349
19. C.J. Currie, P. McEwan, J.R. Peters, T.C. Patel, and S. Dixon The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): Descriptive analysis from the first 20,000 subjects Value Health. 8 2005 581 590
20. C.J. Currie, C.L. Morgan, C.D. Poole, P. Sharplin, M. Lammert, and P. McEwan Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes Curr Med Res Opin. 22 2006 1523 1534
21. H. Barry, M. Ebell, and J. Hickner Evaluation of suspected urinary tract infection in ambulatory women: A cost-utility analysis of office-based strategies J Fam Pract. 44 1997 49 60
22. S. Lane, A.R. Levy, J. Mukherjee, J. Sambrook, and H. Tildesley The impact on utilities of differences in bodyweight among Canadian patients with type 2 diabetes Curr Med Res Opin 30 2014 1267 1273
23. Health Survey for England 2003 [consultado 1 Jul 2013]. Disponible en: http://www.dh.gov.uk/PublicationsAndStatistics/PublishedSurvey/HealthSurveyForEngland/HealthSurveyResults/HealthSurveyResultsArticle/fs/en?CONTENT-ID=4098913&chk=4DPdlh
24. Ministerio de Sanidad, Servicios Sociales e Igualdad. Explotación del CMBD [consultado 1 Jul 2013]. Disponible en: http://pestadistico.inteligenciadegestion.msssi.es/
25. Gisbert R, Brosa M. Base de Datos de Costes Sanitarios eSalud. Barcelona, 2013 [consultado 1 Jul 2013]. Disponible en: http://www.oblikue.com
26. S. Moreno, A. Pastor, L. Betegón, and F. Pérez Análisis de coste efectividad del uso de dronedarona a largo plazo en el tratamiento de la fibrilación auricular en España Rev Esp Econ Salud. 10 2011 3 13
27. A. Hervás-Angulo, J.M. Cabasés-Hita, and T. Forcén-Alonso Costes del ictus desde la perspectiva social. Enfoque de incidencia retrospectivo con seguimiento a 3 años Rev Neurol. 43 2006 518 525
28. B. Schwarz, M. Gouveia, J. Chen, G. Nocea, K. Jameson, J. Cook, and et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy Diabetes Obes Metab. 10 Suppl 1 2008 43 55
29. M. Hammer, M. Lammert, S.M. Mejías, W. Kern, and B.M. Frier Costs of managing severe hypoglycaemia in three European countries J Med Econ. 12 2009 281 290
30. World Health Organization. ATC/DDD Index WHO Collaborating Centre of Drug Statistics Methodology. 2013 [consultado 1 Jul 2013]. Disponible en: http://www.whocc.no/atc-ddd-index/
31. Consejo General del Colegio Oficial de Farmacéuticos [consultado 1 Jul 2013]. Disponible en: http://www.portalfarma.com
32. Counterweight Project Team Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care J Health Serv Res Policy. 13 2008 158 166
33. J.A. Sacristán, J. Oliva, J. del Llano, L. Prieto, and J.L. Pinto ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 16 2002 334 343
34. C. Clar, J.A. Gill, R. Court, and N. Waugh Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes BMJ Open. 2 2012 e001007
35. H.G. Van Haalen, M. Pompen, K. Bergenheim, P. McEwan, R. Townsend, and M. Roudaut Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands Clin Drug Investig. 34 2014 135 146
36. P. Clarke, A. Gray, R. Legood, A. Briggs, and R. Holman The impact of diabetes-related complications on healthcare costs: Results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) Diabet Med. 20 2003 442 450
37. National Institute for Health and Care Excellence. Final appraisal determination - dapagliflozin in combination therapy for treating type 2 diabetes. Issue date: May 2013 [consultado 1 Jul 2013]. Disponible en: http://www.nice.org.uk/nicemedia/live/13722/63966/63966.pdf